BiotechTube

CT-P17 + EU-approved Humira

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Chronic Plaque Psoriasis

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Trial Timeline

Nov 7, 2022 → Feb 5, 2024

NCT ID
NCT05495568

About CT-P17 + EU-approved Humira

CT-P17 + EU-approved Humira is a phase 3 stage product being developed by Celltrion for Moderate to Severe Chronic Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05495568. Target conditions include Moderate to Severe Chronic Plaque Psoriasis.

What happened to similar drugs?

7 of 20 similar drugs in Moderate to Severe Chronic Plaque Psoriasis were approved

Approved (7) Terminated (2) Active (12)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
🔄CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄Afimkibart + PlaceboChugai PharmaceuticalPhase 3
🔄CS-3150Daiichi SankyoPhase 3
✅tacrolimusAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05495568Phase 3Completed

Competing Products

20 competing products in Moderate to Severe Chronic Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
PexidartinibDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
Ranirestat + PlaceboEisaiPhase 2/3
38
E6007 + PlaceboEisaiPhase 2
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
35
KHK4827 + PlaceboKyowa KirinPhase 2
35
Stelara + Bmab1200BioconPhase 3
40
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
40